Hamidreza Jamilian

Hamidreza Jamilian

Auto-generated profile, based on publicly available information

Hamidreza Jamilian

Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SAS Akhondzadeh
S Akhondzadeh
ESE Shasavand
E Shasavand
HJH Jamilian
H Jamilian
OSO Shabestari
O Shabestari
AKA Kamalipour
A Kamalipour
Objective: There is growing interest in investigating the adenosine–dopamine interaction in the ventral striatum. Adenosine plays a role opposite to dopamine in the striatum and adenosine antagonist...

26 April 2012 in International Journal of Psychiatry in Clinical Practice
Verified
Journal Article
Closed access
HJHamidreza Jamilian
Hamidreza Jamilian
KBKamran Bagherzadeh
Kamran Bagherzadeh
ZNZeinab Nazeri
Zeinab Nazeri
MHMarzieh Hassanijirdehi
Marzieh Hassanijirdehi
Vitamin D deficiency has been associated with an increased risk of depression and schizophrenia. The aim was to compare serum levels of vitamin D, calcium, phosphorus and parathyroid hormone in schizophrenics, depressed patients and healthy subjects in an Iranian population. In a cross-sectional study, 100 patients with schizophrenia and 100 with major depression were enrolled. A questionnaire was filled by using medical records of patients. After that a serum sample was taken and levels of vitamin D, calcium, phosphorus and parathyroid hormone were assessed and then compared between the three groups. Post-hoc analysis of Tukey showed that vitamin D level in healthy participants was significantly higher than depressed patients and schizophrenics while there was no significant difference between vitamin D level in depressed and schizophrenic patients. The findings suggest that vitamin D affects the brain independent of hormonal pathways which regulate serum level of calcium. Non-significant difference in the serum level of vitamin D between the schizophrenics and the depressed patients suggests that the independent effect of vitamin D in brain is a general effect and is not specialized to a specific region or pathway in the brain; however, differences between psychiatric and non-psychiatric patients might be resulted from differences in psychosocial backgrounds.

18 September 2014 in Global Journal of Health Science
Verified
Journal Article
Open access
PDF file
HJHamidreza Jamilian
Hamidreza Jamilian
HSHasan Solhi
Hasan Solhi
MJMehri Jamilian
Mehri Jamilian
Introduction: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investigated the efficacy of omega-3 fatty acid as add-on treatment in schizophrenia. Material & Methods: A randomized, double blind, placebo controlled fixed-dose, add-on clinical trial conducted over 8 weeks. 60 patients with documented schizophrenia randomly divided into two groups: omega-3(1000 mg/day) (n=30) and placebo (n=30). Patients received omega-3 or placebo in addition to their standard antipsychotic treatment. Patient follow up was done using Positive and Negative syndrome Scale (PANSS). Data analyzed using SPSS software v.20. Result: At the end of 8 weeks treatment, PANSS score decreased significantly in both groups (p<0.05) in comparison to baseline. Efficacy of omega-3 in decreasing general psychopathologic and total scores was significant in comparison to placebo group from 4 and 6 weeks after onset of treatment, respectively (p0.05). Conclusion: we found that supplemental omega-3 might increase efficacy of conventional antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions and availability of omega-3 made this substance a potential supplement in improved treatment of schizophrenia

21 February 2017 in Gynecological Endocrinology
Verified
Journal Article
Closed access
HJHamidreza Jamilian
Hamidreza Jamilian
MJMehri Jamilian
Mehri Jamilian
MSMansooreh Samimi
Mansooreh Samimi
FEFaraneh Afshar Ebrahimi
Faraneh Afshar Ebrahimi
MRMaryam Rahimi
Maryam Rahimi
ZAZatollah Asemi
Zatollah Asemi
Introduction: Limited data are available assessing the effects of oral carnitine supplementation on mental health parameters and biomarkers of oxidative stress of women with polycystic ovary syndrome (PCOS).This study was designed to determine the effects of oral carnitine supplementation on mental health parameters and biomarkers of oxidative stress in women with PCOS. Methods: In the current randomized, double-blind, placebo-controlled trial, 60 patients diagnosed with PCOS were randomized to take either 250 mg carnitine supplements (n = 30) or placebo (n = 30) for 12 weeks. Results: After 12 weeks’ intervention, compared with the placebo, carnitine supplementation resulted in a significant improvement in Beck Depression Inventory total score (−2.7 ± 2.3 versus −0.2 ± 0.7, p < 0.001), General Health Questionnaire scores (−6.9 ± 4.9 versus −0.9 ± 1.5, p < 0.001) and Depression Anxiety and Stress Scale scores (−8.7 ± 5.9 versus −1.2 ± 2.9, p = 0.001). In addition, changes in plasma total antioxidant capacity (TAC) (+84.1 ± 151.8 versus +4.6 ± 64.5 mmol/L, p = 0.01), malondialdehyde (MDA) (−0.4 ± 1.0 versus +0.5 ± 1.5 μmol/L, p = 0.01) and MDA/TAC ratio (−0.0005 ± 0.0010 versus +0.0006 ± 0.0019, p = 0.003) in the supplemented group were significantly different from the changes in these indicators in the placebo group. Conclusions: Overall, our study demonstrated that carnitine supplementation for 12 weeks among patients with PCOS had favorable effects on parameters of mental health and biomarkers of oxidative stress.

1 January 2016 in Annals of Cardiac Anaesthesia
Verified
Journal Article
Open access
PDF file
HMHesameddin Modir
Hesameddin Modir
EMEsmail Moshiri
Esmail Moshiri
NBNiknam Bagheri
Niknam Bagheri
AMAbolfazl Mohammadbeigi
Abolfazl Mohammadbeigi
HJHamidreza Jamilian
Hamidreza Jamilian
BEBabak Eshrati
Babak Eshrati
Introduction: Electroconvulsive therapy (ECT) is an effective treatment for many mental disorders, especially severe and persistent depression, bipolar disorder, and schizophrenia. The aim of this study is to compare the effect of dexmedetomidine and alfentanil on agitation, satisfaction, seizure duration, and patients hemodynamic after ECT. Materials and Methods: In a three phase crossover randomized clinical trial, 75 patients aged between 18 and 50 years and candidate for ECT were enrolled and assigned into three groups (25 patients in each group). All patients, respectively, took premedication of dexmedetomidine, alfentanil, or saline in three consecutive phases. Patients received 0.5 μg/kg dexmedetomidine, 10 μg/kg alfentanil or normal saline intravenously, 10 min before induction. Finally, seizure and recovery duration, satisfaction and agitation score, and hemodynamic parameters were evaluated. Results: There was no significant difference about seizure duration, agitation score, and hemodynamic parameters between groups but recovery duration was significantly lower in the control group than dexmedetomidine (P = 0.016) and alfentanil group (P = 0.0001). Patients' satisfaction was significantly higher in intervention groups (alfentanil and dexmedetomidine groups) (P = 0.0001). Conclusion: Given the equal effects of alfentanil and dexmedetomidine, it seems that choosing one of these two drugs for premedication of patients undergoing ECT is appropriate. Drug choice is influenced by numerous factors such as accessibility of each drug and the dominance of anesthesiologist and psychiatrist.

18 September 2014 in Global Journal of Health Science
Verified
Journal Article
Open access
PDF file
HJH. R. Jamilian
H. R. Jamilian
AMA. A. Malekirad
A. A. Malekirad
MFM. Farhadi
M. Farhadi
MHMojtaba Habibi
Mojtaba Habibi
NZN. Zamani
N. Zamani
Introduction: The purpose of this study is to measure Effectiveness of group dialectical behavior therapy (basedon core distress tolerance and emotion regulation components) on Expulsive Anger and Impulsive Behaviors. Materials & Methods: Research method is a semi experimental socio-statistic approach consisting of experimental group (dialectical behavior therapy) and control group. Participants were patients referred to Amir Kabir Hospital in Arak who suffered from Expulsive Anger and Impulsive Behaviors. Based on stratified random sampling, 16 patients (women) were placed in each group. Research tools included the structured diagnosis interview according to DSM-IV-TR (2000), Barrat impulsivity scale(1994) Distress Tolerance Scale (2005) Difficulties of Emotion Regulation Scale (2004) and dialectical behavior therapy were done for two months,8 group-sessions). Findings: Dialectical behavior therapy was effective on Expulsive Anger and Impulsive Behaviors. Discussion & Conclusion: Distress tolerance and emotion regulation components were effective on Expulsive Anger and Impulsive Behaviors.